Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SLDB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SLDB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Solid Biosciences LLC

SLDB
Current price
5.26 USD -0.05 USD (-0.94%)
Last closed 5.42 USD
ISIN US83422E2046
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 420 133 472 USD
Yield for 12 month -33.50 %
1Y
3Y
5Y
10Y
15Y
SLDB
21.11.2021 - 28.11.2021

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. Address: 500 Rutherford Avenue, Charlestown, MA, United States, 02129

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

15.50 USD

P/E Ratio

Dividend Yield

Financials SLDB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SLDB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

+3 124 000 USD

Current Year

-2 455 000 USD

Last Year

-76 563 000 USD

Current Quarter

Last Quarter

+1 562 000 USD
EBITDA -140 383 008 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -30.15 %
PEG Ratio
Return On Equity TTM -55.30 %
Wall Street Target Price 15.50 USD
Revenue TTM
Book Value 3.80 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -108 472 000 USD
Earnings per share -3.01 USD
Diluted Eps TTM -3.01 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation SLDB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.16
Price Sales TTM 3.65
Enterprise Value EBITDA -3.69
Price Book MRQ 1.45

Technical Indicators SLDB

For 52 Weeks

2.41 USD 10.37 USD
50 Day MA 3.93 USD
Shares Short Prior Month 8 076 349
200 Day MA 4.58 USD
Short Ratio 4.60
Shares Short 10 140 279
Short Percent 12.39 %